Nermine Laaboub1, Céline Dubath1, Setareh Ranjbar2, Guibet Sibailly1, Claire Grosu1, Marianna Piras1, Didier Délessert3, Hélène Richard-Lepouriel4, Nicolas Ansermot1, Severine Crettol1, Frederik Vandenberghe1, Carole Grandjean1, Aurélie Delacrétaz1,5, Franziska Gamma5, Kerstin Jessica Plessen6, Armin von Gunten7, Philippe Conus8, Chin B Eap9,10,11,12. 1. Unit of Pharmacogenetics and Clinical Psychopharmacology, Department of Psychiatry, Centre for Psychiatric Neuroscience, Lausanne University Hospital, University of Lausanne, 1008 Prilly, Prilly, Switzerland. 2. Center for Psychiatric Epidemiology and Psychopathology, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland. 3. Prison Medicine and Psychiatry Service, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland. 4. Unit of Mood Disorders, Department of Psychiatry, Geneva University Hospital, Geneva, Switzerland. 5. Les Toises Psychiatry and Psychotherapy Center, Lausanne, Switzerland. 6. Service of Child and Adolescent Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland. 7. Service of Old Age Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland. 8. Service of General Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland. 9. Unit of Pharmacogenetics and Clinical Psychopharmacology, Department of Psychiatry, Centre for Psychiatric Neuroscience, Lausanne University Hospital, University of Lausanne, 1008 Prilly, Prilly, Switzerland. chin.eap@chuv.ch44. 10. School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland. chin.eap@chuv.ch44. 11. Center for Research and Innovation in Clinical Pharmaceutical Sciences, University of Lausanne, Lausanne, Switzerland. chin.eap@chuv.ch44. 12. Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Lausanne, Switzerland. chin.eap@chuv.ch44.
Publisher Correction: BMC Psychiatry 22, 342 (2022)https://doi.org/10.1186/s12888-022-03983-3Following the publication of the original article [1], the authors identified errors in the figure captions.Fig. 1
aDefined using the International Diabetes Federation definition; bBMI by 10 kg.m-2. c Estimated risk of death from cardiovascular diseases within 10 years using the Systematic Coronary Risk Estimation. Models were adjusted for age, sex, smoking status, and psychotropic medication (classified by the risk of weight gain), except the model for CVD which was adjusted only for psychotropic medication. 1 Models fitted with random effect at observation level. 2 Models fitted with random effect at patient level. ***: p-value < 0.001; **: p-value ≤ 0.01; *: p-value ≤ 0.05. Correction for multiple testing was applied using false discovery rate. Abbreviations: BMI body mass index, CVD cardiovascular diseases, HDL high-density lipoprotein, MetS metabolic syndrome, N numberFig. 2 Model for FPG was adjusted for time, age, sex, smoking status and psychotropic medication. Model for TG was adjusted for time, age, interaction between age and insomnia disorders, sex, smoking status, setting of care (in/outpatient) and psychotropic medication. Model for HDL-C was adjusted for time, age, interaction between age and insomnia disorders, smoking status and psychotropic medication. Model for LDL-C was adjusted for time, age, interaction between age and insomnia disorders, sex and smoking status. Model for Total-C was adjusted for time, age, sex, interaction between age and insomnia disorders, sex, smoking status and psychotropic medication. Models for 10-year CVD risks (FRS and SCORE) were adjusted for time and psychotropic medication. ***:p-value < 0.001; **p-value < 0.01; *:p-value ≤ 0.05. Correction for multiple testing was applied using false discovery rate. Abbreviations: FPG fasting plasma glucose, FRS Framingham Risk Score, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, N number, SCORE Systematic Coronary Risk Estimation, Total-C total cholesterol, TG triglyceridesFig. 3 Models for BMI and waist circumference were adjusted for time, age, interaction between age and insomnia disorders, sex, smoking status, and psychotropic medication. Model for diastolic blood pressure was adjusted for time, age, interaction between age and insomnia disorders, sex and psychotropic medication. ***:p-value < 0.001; **: p-value < 0.01;*:p-value ≤ 0.05. Correction for multiple testing was applied using false discovery rate. Abbreviations: BMI body mass index, N numberThe original article [1] has been corrected.